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Purpose: Although diabetes is recognized as a risk
factor for the development of cognitive impairment
and for accelerated progression to Alzheimer disease
(AD), it is unclear whether patients with diabetes who
have already progressed to AD have a different rate of
cognitive and functional decline compared with that in
those without diabetes. This post hoc exploratory
analysis compared cognitive and functional decline
over an 18-month period in patients with mild AD
dementia with and without comorbid diabetes. Decline
in quality of life was assessed as a secondary objective.
Methods: In a post hoc exploratory analysis, we
analyzed data from the placebo groups of three
18-month, randomized, placebo-controlled trials of sol-
anezumab and semagacestat in patients with AD. Data
from patients with mild AD dementia (Mini-Mental State
Examination [MMSE] score, 20–26) and comorbid
diabetes at baseline were compared with data from
patients with mild AD dementia without diabetes at
baseline. Cognition was assessed using the 14-item AD
Assessment Scale–Cognitive Subscale (ADAS-Cog14) and
the MMSE. Functioning was assessed with the AD
Cooperative Study–Activities of Daily Living Inventory
(instrumental subset) (ADCS-iADL). Quality of life was
assessed using the European Quality of Life–5 Dimen-
sions scale, proxy version (proxy utility score and visual
analog scale score), and the Quality of Life in AD scale,
self-report and proxy (caregiver) versions. GroupAccepted for publication January 6, 2015.
http://dx.doi.org/10.1016/j.clinthera.2015.01.002
0149-2918/$ - see front matter
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
June 2015comparisons of changes from baseline to 18 months in
cognitive, functional, and quality-of-life measures em-
ployed a repeated-measures model adjusted for propen-
sity score, study, baseline cognition score (functional or
quality of life), age, sex, level of education, genotype of
the apolipoprotein E gene, and concurrent use of an
acetylcholinesterase inhibitor or memantine.
Findings: At baseline, patients with mild AD
dementia with and without diabetes did not signiﬁ-
cantly differ on the cognitive measures, but those
without diabetes were functioning at a signiﬁcantly
higher level. At 18 months, compared with patients
without diabetes, those with diabetes showed a nu-
merically but statistically nonsigniﬁcantly lesser cog-
nitive decline (least squares mean between-group
differences: ADAS-Cog14 score, 1.61 [P ¼ 0.21];
MMSE score, –0.40 [P ¼ 0.49]) and a statistically
signiﬁcantly lesser functional decline (least squares
mean between-group difference in ADCS-iADL score,
–3.07; P ¼ 0.01). The 2 groups did not differ on
declines in the quality-of-life measures.
Implications: The present ﬁndings suggest that
diabetes may inﬂuence the rate of functional decline
among patients with mild AD dementia. These results
require replication in studies that address the limita-
tions of the present post hoc exploratory analysis and
that explore the potential causes of the observed
differences. (Clin Ther. 2015;37:1195–1205) & 2015
The Authors. Published by Elsevier HS Journals, Inc.Scan the QR Code with your phone to obtain
FREE ACCESS to the articles featured in the
Clinical Therapeutics topical updates or text
GS2C65 to 64842. To scan QR Codes your
phone must have a QR Code reader installed.
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INTRODUCTION
Alzheimer disease (AD) and type 2 diabetes are
chronic diseases that may share common pathologic
features (eg, amyloid formation),1–3 in addition to
being linked to the aging process.4 Diabetes is
associated with the development of cognitive
impairment5–8 and with accelerated progression to
dementia due to AD.9 Some evidence suggests that AD
is associated with a brain-speciﬁc type of insulin
resistance and that insulin signaling may be attenuated
in parts of the brain in patients with AD.10,11 Insulin
receptors are found in the memory-foundation regions
of the brain,12 and it is speculated that stimulation of
insulin-receptor signaling in these brain regions with
some of the glucose-lowering drugs, such as insulin,
thiazolidinediones, and glucagon-like polypeptide-1 re-
ceptor agonists, may beneﬁt patients with AD. Clinical
trials of glucose-lowering drugs as alternative treat-
ments in patients with AD have been undertaken.13–16
The association between mild cognitive impair-
ment and diabetes is known.17,18 Mild cognitive
impairment represents a transitional phase between
normal cognitive function and dementia, although
not all people with mild cognitive impairment prog-
ress to develop dementia.19 It is unclear whether
diabetic patients who have already progressed to
dementia due to AD experience a different rate of
further cognitive and functional decline over time
compared with that in patients with AD without
diabetes. We hypothesized that the presence of
comorbid diabetes is associated with a faster rate of
decline in patients with AD. Therefore, we aimed to
assess whether patients with mild AD dementia and
comorbid diabetes show a greater magnitude of
cognitive and functional decline compared with
those without comorbid diabetes. The focus on
patients with mild AD dementia, rather than
moderate or severe AD dementia, was driven by the
growing recognition that patients with mild AD
dementia are more likely to beneﬁt from disease-
modifying interventions, reﬂecting a greater potential
for change in the progression of the disease.20,21
The primary objective of this post hoc exploratory
analysis was to compare cognitive and functional
decline over 18 months between patients with mild1196AD dementia with and without a comorbid diabetes
diagnosis. As a secondary objective, this analysis
compared the decline in quality of life in patients with
mild AD dementia with and without comorbid dia-
betes. In addition, as an exploratory objective, we
repeated the analyses on data from patients with
moderate AD dementia.
PATIENTS AND METHODS
Analysis Population
This post hoc exploratory analysis used data from the
placebo groups of three 18-month, randomized, placebo-
controlled trials of solanezumab and semagacestat in
patients with AD.22,23 The analysis population was
created from the intent-to-treat populations of the
placebo groups. Speciﬁcally, patients with mild AD
dementia (Mini-Mental State Examination [MMSE]
score, 20–26) and comorbid diabetes at baseline were
compared with patients with mild AD without diabetes
at baseline. The analysis was repeated on data from
patients with moderate AD dementia (MMSE score, 16–
19), comparing those with comorbid diabetes at baseline
to those with without diabetes at baseline.
Patient Consent
The parent studies22,23 received ethical approval
from the governing institutional review boards, and
patients and caregivers provided written informed
consent in accordance with the Declaration of
Helsinki.
Assessment of Diabetes
The presence of diabetes as a condition comorbid
with AD was assessed at baseline as a part of patient-
reported medical comorbidities. For the purposes of the
present analyses, comorbid diabetes was deﬁned as the
presence of at least 1 of the following criteria: baseline
random blood glucose concentrationZ200 mg/dL (11.1
mmol/L), patient-reported preexisting diabetes at or
before baseline, and/or reported use of any glucose-
lowering medication at or before baseline (a sulfonylurea
[tolbutamide, glibenclamide, gliclazide, glimepiride, gli-
pizide, glibenclamide/metformin], a biguanide [bufor-
min, metformin], a thiazolidinedione [pioglitazone,
rosiglitazone, pioglitazone/metformin, rosiglitazone/met-
formin], an α-glucosidase inhibitor [acarbose, miglitol,
voglibose], a dipeptidyl peptidase 4 inhibitor [saxaglip-
tin, sitagliptin, vildagliptin, sitagliptin/metformin], a
meglitinide [nateglinide, repaglinide], glucagon-likeVolume 37 Number 6
H. Ascher-Svanum et al.peptide-1 receptor agonists [exenatide], insulins [insulin
human, insulins and analogues, insulin aspart, insulin
bovine, insulin lispro, insulin porcine, insulin lispro
human analogue þ protamine, recombinant human
insulins, insulin aspart þ protamine, insulin detemir,
insulin glargine], and/or epalrestat). Patients who did
not meet any of the preceding criteria were categorized
as being without comorbid diabetes. No information
was available on the type of diabetes, duration of
diabetes, or its severity.
Measures of Cognition, Functioning, and Quality
of Life
Cognitive decline was measured by the 14-item AD
Assessment Scale–Cognitive subscale [ADAS-Cog14]
and the MMSE. The ADAS-Cog14 was designed to
assess cognitive impairment in persons with AD; total
scores range from 0 to 90, with higher scores indicat-
ing greater disease severity.24 The MMSE is a brief,
2-part measure used for assessing cognitive function.25
The range of the total MMSE score is 0 to 30, with
lower scores indicating greater severity of disease.
Functional decline was measured with the AD Co-
operative Study–Activities of Daily Living Inventory
(instrumental subset) [ADCS-iADL]).26 The ADCS-
iADL is an inventory developed as a rater-
administered questionnaire that is answered by the
patient’s caregiver. The caregiver is asked whether the
patient has attempted activities of daily living within the
preceding 4 weeks. If the patient has done so, the
caregiver is asked to rate the patient’s performance level
based on a set of performance descriptions. Scores range
from 0 to 56, with higher scores indicating better
functioning in performing activities of daily living.
Quality of life was assessed using 4 health-related
quality-of-life measures: the European Quality of Life–
5 Dimensions (EQ-5D)27; the Health-Related Quality
of Life Scale, proxy version, utility score; the EQ-5D
visual analog scale score; and the Quality of Life
in AD scale, self-report and caregiver versions28,29
(QoL-AD-Self and QoL-AD-Caregiver, respectively).
Baseline Characteristics
The baseline characteristics of the analysis popula-
tion were summarized by mild AD with and without
comorbid diabetes at baseline and overall. Summaries
included descriptive statistics for continuous and
categorical measures. The Fisher exact test or Pearson
χ2 test was used for comparing the categorical dataJune 2015between the diabetic and nondiabetic groups. For
continuous data, ANOVA was used.
Statistical Analysis
The 3 studies from which the data were extracted
were not designed for investigating the relationships
between diabetes and AD progression. A propensity
score was applied to each patient to adjust for
potential imbalance in core baseline characteristics
(ie, age, body mass index [BMI], sex, and antihyper-
tensive drug use) between the diabetic and nondiabetic
groups. The propensity score in each patient was
calculated using a logistic regression model, with
diabetes status as the dependent variable and with
baseline age, BMI, sex, and antihypertensive drug use
at baseline as independent variables.
Declines in cognition, functioning, and quality-of-
life measures over the 18-month study were assessed
as absolute magnitudes of change from baseline to 18
months (week 7622 or 8023).
Cognitive decline over 18 months was assessed
using the ADAS-Cog14 and MMSE, with between-
group comparisons made using a mixed-effects,
repeated-measures (MMRM) model adjusted for pro-
pensity score, study, baseline score, age, sex, level of
education (stratiﬁed as o8, 8–12, and 412 years),
genotype of the apolipoprotein E gene (APOE), and
concurrent use of an acetylcholinesterase inhibitor
(AChEI) or memantine. Two sensitivity analyses were
conducted to assess the robustness of the ﬁndings
(details in the Sensitivity Analyses section).
Functional decline was assessed using the ADCS-
iADL, which employed an MMRM model adjusted for
propensity score, study, baseline score, age, sex, level of
education, APOE genotype, and concurrent AChEI or
memantine use. A similar analysis was conducted on
data from each of the 4 quality-of-life measures.
These analyses were repeated on data from patients with
moderate AD. All data analyses were carried out using SAS
version 9.2 (SAS Institute Inc, Cary, North Carolina).
Sensitivity Analyses
Two sensitivity analyses were employed for each
instrument—ADAS-Cog14, MMSE, and ADCS-iADL
—by changing the generation of propensity score. The
ﬁrst new propensity score was created based on sex,
BMI, and age only, excluding antihypertensive drug
use from the original model. Antihypertensive drug
use was then added as a covariate in the primary1197
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score, study, baseline score, visit, baseline age, sex,
diabetes status at baseline, level of education (stratiﬁed
as o8, 8–12, and 412 years), APOE genotype, and
concurrent AChEI or memantine use. Similarly, the
second new propensity score was created based on sex
and age only, excluding antihypertensive drug use and
BMI from the original model. BMI was added to the
primary MMRM model as a covariate along with the
new propensity score, study, baseline score, visit, base-
line age, sex, diabetes status at baseline, level of
education (stratiﬁed as o8, 8–12, and 412 years),
APOE genotype, and concurrent AChEI or memantine
use. The statistical adjustment included BMI because a
previous study found that the risk for cognitive decline
was decreased among overweight and obese patients.30
RESULTS
Baseline Characteristics of Patients with Mild AD
A total of 972 patients with mild AD (113 diabetic
and 859 nondiabetic) were included in the analysis and
were followed up for 18 months (Table). The groups
with and without diabetes did not signiﬁcantly differ in
terms of years of education, substance (alcohol, caffeine,
or tobacco) use, APOE ε4 carrier status, work status,
time since onset of AD symptoms, or time since AD
diagnosis. Patients with diabetes were statistically
signiﬁcantly more likely to be male, have a greater
BMI, have a higher baseline Neuropsychiatric Inven-
tory score, and be using a blood glucose–lowering and/or
antihypertensive drug. The diabetic patients had a
statistically signiﬁcant lower (poorer) mean baseline
functional (ADCS-iADL) score compared with the
nondiabetic patients. The patients without diabetes felt
better at baseline than did the patients with diabetes
(QoL-AD-Self).
Changes in Cognition
These patients with mild AD with or without diabetes
had worsening on both cognitive measures—ADAS-
Cog14 and MMSE—at the end of the follow-up period
(Figures 1 and 2). The between-group difference in score
on either measure was not statistically signiﬁcant (least
squares mean [LSM] differences at 18 months: ADAS-
Cog14, –1.61 [95% CI, –4.16 to 0.93; P = 0.21]; MMSE,
–0.40 [95% CI, –1.52 to 0.73; P = 0.49]). Compared
with the group without diabetes, the diabetic group
showed numerically, but not statistically signiﬁcantly,
lesser declines (by 26% on the ADAS-Cog14 and by119820% on the MMSE). The 2 sensitivity analyses yielded
similar results.
Changes in Functional Ability
Although all of the patients with mild AD had
functional decline over the follow-up period
(Figure 3), the patients with diabetes demonstrated a
signiﬁcantly lesser magnitude of decline at 18 months
(LSM difference on ADCS-iADL, –3.07; 95% CI,
0.62–5.53; P ¼ 0.01). The 3.07-point difference
translates into 46% lesser decline in the diabetes
group. During the 18-month follow-up, the nondia-
betic group had a decline of 5.87, from 43.00 to
37.13, whereas the diabetic group changed very little
on the ADCS-iADL measure (decline of 0.54 points,
from 40.77 to 40.23). The 2 sensitivity analyses
provided essentially the same, signiﬁcant, results.
Changes in Quality of Life
Scores on all 4 quality-of-life measures suggested
declines in both patient groups at 18 months, except in
patients with diabetes on the EQ-5D utility score, which
remained similar. The magnitudes of change from base-
line to 18 months were not signiﬁcantly different between
the diabetic and nondiabetic groups on any of the 4
quality-of-life measures. On the ED-5Q visual analog
scale measure, the LSM difference at 18 months was 1.86
(95% CI, –2.94 to 6.66; P ¼ 0.45). On the EQ-5D utility
score, the LSM difference was –0.02 (95% CI, –0.08 to
0.03; P ¼ 0.41). The LSM differences on the QoL-AD-
Caregiver and QoL-AD-Self scales in patients with mild
AD with and without comorbid diabetes were –1.00
(95% CI, –2.50 to 0.51; P ¼ 0.45) and –0.11 (95% CI, –
1.54 to 1.32; P ¼ 0.88), respectively.
Patients with Moderate AD
When the analyses were repeated in patients with
moderate AD dementia with (n ¼ 59) and without (n ¼
494) diabetes, the 2 groups did not signiﬁcantly differ on
baseline characteristics, except for a longer time since
AD diagnosis before baseline in the diabetic patients (3.2
years vs 2.6 years in the nondiabetic patients; P ¼ 0.05)
and having 1 or more primary relatives with AD (19%
of the diabetic patients had a primary relative with AD,
whereas 36% of the nondiabetic patients had a primary
relative with AD; P ¼ 0.01) (data not shown).
When compared on magnitude of decline in cogni-
tive, functional, and quality-of-life measures over the
18-month study, the patients with moderate ADVolume 37 Number 6
Table. Baseline demographic and clinical characteristics of the diabetic and nondiabetic patients with mild
Alzheimer disease (intent to treat).
Characteristic
Diabetic
(n ¼ 113)
Nondiabetic
(n ¼ 859) P
Sociodemographic
Age, mean (SD), y 74 (8) 74 (8) 0.491
Male sex, no. (%) 64 (56.6) 393 (45.8) 0.029
Race, no. (%) 0.600
White 91 (80.5) 728 (84.7)
Asian 16 (14.2) 105 (12.2)
Hispanic 4 (3.5) 12 (1.4)
Other 2 (1.8) 14 (1.6)
Education, years, mean (SD) 12.3 (3.9) 12.6 (3.9) 0.410
Work status, no. (%) 0.271
Retired 92 (81.4) 732 (85.2)
Unable to work 9 (8.0) 48 (5.6)
Full-time 6 (5.3) 21 (2.4)
Part-time 5 (4.4) 37 (4.3)
Volunteer work 1 (0.9) 21 (2.4)
Does not live alone or own home, no. (%) 100/107 (93.5) 724/818 (88.5) 0.123
Clinical
BMI, mean (SD), kg/m2 27.4 (4.9) 25.2 (4.2) o0.001
Risk factors, no. (%)
Substance use
Caffeine 47/70 (67.1) 405/593 (68.3) 0.845
Alcohol 35 (31.0) 347 (40.4) 0.054
Tobacco 6 (5.3) 63 (7.3) 0.431
APOE
ε4 carrier 53/101 (52.5) 466/782 (59.6) 0.172
Genotype
ε2/ε4 2/101 (2.0) 25/782 (3.2)
ε3/ε4 41/101 (40.6) 328/782 (41.9)
ε4/ε4 10/101 (9.9) 113/782 (14.5)
Primary relative(s) with AD 43/99 (43.4) 309/787 (39.3) 0.424
AD history
Time since onset of AD symptoms, mean (SD), y 4.0 (2.6) 4.3 (2.6) 0.330
Time since AD diagnosis, mean (SD), y 1.8 (1.8) 2.0 (1.8) 0.417
AD scale scores
GDS
Mean (SD) score 1.8 (1.5) 1.9 (1.5) 0.600
Status, no. (%) 1.000
6 (at least mild depression) 2 (1.8) 16 (1.9)
r5 (normal) 111 (98.2) 843 (98.1)
MMSE score, mean (SD)
Visit 1, screening 22.9 (2.0) 22.9 (2.0) 0.878
Visit 2, baseline 22.6 (2.8) 22.6 (2.8) 0.978
(continued)
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Characteristic
Diabetic
(n ¼ 113)
Nondiabetic
(n ¼ 859) P
Modiﬁed HIS, mean (SD) 0.9 (0.8) 0.7 (0.8) 0.119
ADAS-Cog14 score, mean (SD) 29.2 (9.7) 29.5 (8.6) 0.667
ADCS-iADL score, mean (SD) 40.8 (11.1) 43.0 (9.6) 0.024
EQ-5D score, mean (SD)
VAS 70.3 (21.0) 71.7 (21.7) 0.516
Utility 0.82 (0.14) 0.85 (0.13) 0.068
QoL-AD, mean (SD)
Self 36.4 (5.3) 38.1 (6.1) 0.037
Caregiver 34.0 (5.9) 35.3 (6.1) 0.114
NPI total score, mean (SD) 11.9 (13.0) 9.0 (11.1) 0.012
Current treatment, no. (%)*
AChEI/memantine 93 (82.3) 758 (88.2) 0.072
Antidiabetic 82/113 (72.6) – –
Antihypertensive 73 (64.6) 371 (43.2) o0.001
Insulin† 17 (15.0) – –
AChEI ¼ acetylcholinesterase inhibitor; AD¼ Alzheimer disease; ADAS-Cog14 ¼ 14-item Alzheimer’s Disease Assessment Scale–
Cognitive subscale (scale: 0– 90, with higher scores indicating greater disease severity); ADCS-iADL ¼ Alzheimer’s Disease
Cooperative Study–Activities of Daily Living Inventory (instrumental subset) (scale: 0–56, with higher scores indicating better
functioning in performing activities of daily living); APOE ¼ apolipoprotein E gene; BMI ¼ body mass index; DDP-4 ¼ dipeptidyl
peptidase 4; GDS ¼ Geriatric Depression Scale (scale: 0-5, normal in elderly with mild-moderate dementia); patients with GDS46
at screening were excluded from trials; EQ-5D ¼ European Quality of Life–5 Dimensions; GLP-1 RA ¼ glucagon-like peptide-1
receptor agonist; HIS ¼ Hachinski Ischemic Scale (scale: o4, primary dementia [eg, Alzheimer disease]; 44 suggest that a
patient’s dementia is likely to be vascular in etiology; these patients were excluded from the trials; 4–7, indeterminate;47, vascular
dementia); MMSE ¼ Mini–Mental State Examination (scale: 0–30, with lower scores indicating greater severity of disease); NPI ¼
Neuropsychiatric Inventory (total of frequency of symptoms [4-point scale] þ severity of symptoms [3-point scale] þ distress
caused by symptoms [5-point scale]); QoL-AD ¼ Quality of Life in Alzheimer’s Disease (13 items rated on a 4- point scale, with 1
being poor and 4 being excellent; scale: 13–52, with higher scores indicated better quality of life); VAS ¼ visual analog scale.
*At baseline, patients were receiving a sulfonylurea (including tolbutamide, glibenclamide, gliclazide, glimepiride, and
glipizide), a biguanide (including buformin and metformin), a thiazolidinedione (including pioglitazone and rosiglitazone),
an α-glucosidase inhibitor (including acarbose, miglitol, and voglibose), a dipeptidyl peptidase 4 inhibitor (including
saxagliptin, sitagliptin, vildagliptin, and sitagliptin/metformin), a meglitinide (including nateglinide and repaglinide),
glibenclamide/metformin, glibenclamide/metformin, pioglitazone/metformin, rosiglitazone/metformin, or epalrestat.
†May have included insulin human, insulin analogues, insulin aspart, insulin bovine, insulin lispro, insulin porcine, insulin lispro
human analogue þ protamine, recombinant human insulin, insulin aspart þ protamine, insulin detemir, or insulin glargine.
Clinical Therapeuticsdementia with and without diabetes did not signiﬁ-
cantly differ on any of the measures.
DISCUSSION
Contrary to our hypothesis, the ﬁndings from the
present post hoc exploratory analysis suggest that
patients with mild AD dementia and comorbid diabetes
did not have greater declines in cognition, functional
ability, or quality of life compared with those in1200patients without diabetes. Unexpectedly, the diabetic
patients were found to have a statistically signiﬁcantly
lesser functional decline from baseline to end point at
18 months compared with that in those without
diabetes, although the patients with AD and diabetes
were functioning at a lower level at baseline. The 2
sensitivity analyses suggested robustness of these ﬁnd-
ings, providing essentially the same results with and
without adjustments for potential confounders such asVolume 37 Number 6
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Figure 1. Cognitive functioning, as measured using the 14-item Alzheimer’s Disease Assessment Scale–
Cognitive Subscale (ADAS-Cog14), in patients with mild Alzheimer disease with and without
comorbid diabetes. Scale: 0 to 90, with higher scores indicating greater disease severity. Analysis
used a propensity score generated by sex, age, body mass index, and antihypertensive treatment
status at baseline as covariates in a mixed-effects, repeated-measures model. The least squares
mean difference at study end was 1.61 (95% CI, –4.16 to 0.93; P ¼ 0.21).
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with a more severe form of AD—those diagnosed with
moderate AD—the groups with and without comorbid
diabetes did not signiﬁcantly differ on decline in any of
the cognitive, functional, or quality-of-life measures.
Although a literature search revealed no published
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community-dwelling patients with AD have reported
diabetes to be associated with a lower magnitude of
cognitive decline.31–33 The ﬁrst study, in 135 patients
with mild to moderate probable or possible AD,
reported that diabetes was associated with a slower
rate of cognitive decline, as measured with the MMSE
and the clinical dementia rating Sum of Boxes, over a–1.53
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Figure 3. Functional decline, as measured using the Alzheimer’s Disease Cooperative Study–Activities of Daily
Living Inventory (instrumental subset) (ADCS-iADL), in patients with mild Alzheimer disease with
and without comorbid diabetes. Scale: 0 to 56, with higher scores indicating better functioning in
performing activities of daily living. Analysis used a propensity score generated by sex, age, body
mass index, and antihypertensive treatment status at baseline as covariates in a mixed-effects,
repeated-measures model. The least squares mean difference at study end was –3.07 (95% CI, 0.62–
5.53; P ¼ 0.01).
Clinical Therapeuticsmean duration of 3 years.31 The second study, in 154
patients with mild to moderate AD who were
followed up for a mean duration of 23 months,
reported that patients with diabetes had a 65%
reduced risk for fast cognitive decline compared with
patients without diabetes.32 Fast decline was deﬁned
as a worsening on the MMSE ofZ5 points. The third
study followed up 608 patients with mild to moderate
AD for a mean duration of 26 months and reported
that patients with diabetes had a signiﬁcantly lesser
cognitive decline compared with those without
diabetes.33 The causes of the more favorable course
of the disease in the patients with diabetes was not
clear; the study authors hypothesized that there may
have been differences in underlying neuropathology
between the 2 groups (eg, the group with diabetes may
have had vascular pathology that contributed to the
initial diagnosis and severity of dementia, but a lower
burden of AD pathology, that led to the slower rate of
decline compared with that in those without
diabetes).33 There also may have been possible
protective effects of the antihypertensive and/or
antidiabetic drugs taken by those with diabetes.31–33
In contrast to the patients in those population-based
studies, the patients in our analysis were participants
in 1 of 3 randomized, placebo-controlled studies of
solanezumab or semagacestat. The use of rigorous1202inclusion and exclusion criteria in these randomized
clinical trials likely resulted in differences between our
group and those treated in usual-care settings.
The present analysis did not ﬁnd that patients with
and without diabetes differed signiﬁcantly in cognitive
decline, but the diabetes group had numerically lesser
magnitudes of decline on both the ADAS-Cog14 and the
MMSE. The observed numeric between-group differ-
ences, which translate into a 26% lesser decline on the
ADAS-Cog14 and a 20% lesser decline on the MMSE,
may be clinically meaningful. In contrast, a 46% lesser
functional decline was seen in the patients with diabetes
compared with that in the patients without diabetes, as
measured by the ADCS-iADL. Our ﬁnding of a signiﬁ-
cant between-group difference in functional decline,
with a numeric but nonsigniﬁcant between-group differ-
ence in cognitive decline, may appear unusual consid-
ering the robust link between cognition and functioning
in AD, in which the functional deﬁcit is thought to be
largely, if not entirely, due to the cognitive deﬁcit.34,35
However, the presence of comorbid conditions may
contribute to functional disability apart from impair-
ments in cognition; patients with diabetes are more
likely to have impairments of balance, vision, and
strength, all of which can interfere with daily function-
ing independent of cognition. It is also possible that the
observed between-group differences in functionalVolume 37 Number 6
H. Ascher-Svanum et al.decline were simply due to a regression to the mean as a
result of differences in baseline functional level, with the
patients without diabetes functioning at a signiﬁcantly
higher level than those with diabetes.36
Most of the diabetic patients in the present analysis
(72.6% [82/113]) were receiving treatment with a
glucose-lowering medication at baseline; 19.5% of
those (16/82) were being treated with insulin. Findings
from recent clinical trials suggest that glucose-lowering
medications may attenuate cognitive impairment in
patients with mild AD.37 Intranasal insulin use has
been reported to delay cognitive decline in murine
models,38 and it has been suggested to preserve
cognitive functioning in a small number of adults
with mild AD.13 A larger-scale study of intranasal
insulin in mild cognitive impairment and mild AD is
underway.37 Glucagon-like peptide-1 analogues are
being tested in patients with AD after a reversal of
memory impairment and reduced plaque loads were
reported in murine models.14,39 Early studies suggested
that rosiglitazone, a thiazolidinedione (peroxisome pro-
liferator-activated receptor γ agonist), might slow cog-
nitive deterioration in APOE ε4 noncarriers with mild
AD; however, a well powered phase 3 study did not
show evidence of beneﬁt.16 Other thiazolidinediones
such as pioglitazone have had promising safety proﬁles
in pilot studies, and further trials are being planned.15
Study Limitations
This post hoc exploratory analysis used data from
patients enrolled in the placebo arms of 3 different studies
of 2 investigational agents for mild to moderate AD; none
of these studies were designed to address the questions
being investigated in the present analysis. Information on
patients’ diabetes was somewhat limited. No information
was collected to help to differentiate between types 1 and
2 diabetes. These two diseases may have different effects
on cognitive decline; however, considering the age dis-
tributions of the study participants and the substantially
greater prevalence of type 2 diabetes versus type 1 in the
general population, it is likely that the majority of patients
had type 2 diabetes.40 Information on the duration of
diabetes, duration of diabetes medication intake, and
hemoglobin A1c measures of diabetes control was not
available. These variables are highly relevant to the
present analysis, as a previous study in older adults
with type 2 diabetes found that the only risk factors
associated with cognitiveimpairment were the duration of
diabetes and hemoglobin A1c level.
41 Furthermore, anJune 2015elevated hemoglobin A1c concentration may be a risk
factor for dementia and cognitive impairment even in
patients who have not yet been diagnosed with diabetes
(“prediabetes”).42 In addition, although recent ﬁndings
have suggested that speciﬁc antidiabetic medications may
help to attenuate cognitive decline,15,43 the small sample
size of the diabetic group in the present analysis did not
allow for a comparison of cognitive decline between the
diabetic patients treated with speciﬁc oral antidiabetic
medications and insulin. Another study limitation was the
lack of information about patients’ β-amyloid status,
which raises the possibility that patients with AD and
diabetes might have included those with mixed or
vascular types of dementia. Last, the present study
included participants from 3 randomized, controlled
studies. This fact raises the potential for selection bias
of the diabetic patients because the studies may have
enrolled patients with well-controlled diabetes, and there-
fore the studied population may not represent the typical
trajectory of decline in patients with comorbid AD and
diabetes treated in usual-care settings.
The main strengths of the current analysis included
its large sample size of patients with AD with and
without comorbid diabetes, the frequent assessments
over the 18-month follow-up period, and the use of
comprehensive and validated assessment tools.
The present ﬁndings will require both replication
and additional investigation in patients treated in
community care to better address the potential limi-
tations of the present analysis and to better understand
the potential determinants of the observed differences.
CONCLUSIONS
The ﬁndings from this post hoc exploratory analysis
suggests that patients with mild AD dementia with
diabetes, although functioning at a lower level at
baseline, manifest signiﬁcantly less functional decline
over an 18-month period compared with those with-
out diabetes, whereas cognitive decline and decline in
quality of life were not found to signiﬁcantly differ
between the 2 groups. The present ﬁndings will
require both replication and additional investigation
in patients treated in community care to better address
the potential limitations of the current analysis.
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